Cogent Biosciences Stock Forecast, Price & News

Cogent Biosciences (NASDAQ:COGT) Frequently Asked Questions

Is Cogent Biosciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cogent Biosciences stock.
View analyst ratings for Cogent Biosciences or view top-rated stocks.

Are investors shorting Cogent Biosciences?

Cogent Biosciences saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,410,000 shares, a drop of 20.8% from the October 31st total of 1,780,000 shares. Based on an average trading volume of 283,700 shares, the short-interest ratio is currently 5.0 days. Approximately 4.1% of the shares of the stock are short sold.
View Cogent Biosciences' Short Interest.

When is Cogent Biosciences' next earnings date?

Cogent Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Cogent Biosciences.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Wednesday, November, 10th. The technology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.07.
View Cogent Biosciences' earnings history.

What price target have analysts set for COGT?

4 equities research analysts have issued 1-year price targets for Cogent Biosciences' stock. Their forecasts range from $20.00 to $31.00. On average, they anticipate Cogent Biosciences' share price to reach $24.33 in the next year. This suggests a possible upside of 214.4% from the stock's current price.
View analysts' price targets for Cogent Biosciences or view top-rated stocks among Wall Street analysts.

Who are Cogent Biosciences' key executives?

Cogent Biosciences' management team includes the following people:

• Andrew R. Robbins, President, Chief Executive Officer & Director
• John L. Green, Chief Financial & Accounting Officer (LinkedIn Profile)
• Jessica Sachs, Chief Medical Officer
• John Robinson, Chief Scientific Officer
• Brad Barnett, Chief Technology Officer

Who are some of Cogent Biosciences' key competitors?

Some companies that are related to Cogent Biosciences include Crinetics Pharmaceuticals (CRNX), DICE Therapeutics (DICE), FibroGen (FGEN), Innoviva (INVA), GH Research (GHRS), Prometheus Biosciences (RXDX), MannKind (MNKD), Centessa Pharmaceuticals (CNTA), Avidity Biosciences (RNA), Vectura Group (VEGPF), MacroGenics (MGNX), Day One Biopharmaceuticals (DAWN), Revance Therapeutics (RVNC), CannTrust (CNTTF) and Arcturus Therapeutics (ARCT).
View all of COGT's competitors.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).

What is Cogent Biosciences' stock symbol?

Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT."

Who are Cogent Biosciences' major shareholders?

Cogent Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.86%), Janus Henderson Group PLC (6.26%), Candriam Luxembourg S.C.A. (4.84%), Commodore Capital LP (4.80%), Polar Capital Holdings Plc (3.08%) and Point72 Asset Management L.P. (2.52%).
View institutional ownership trends for Cogent Biosciences.

Which institutional investors are selling Cogent Biosciences stock?

COGT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Point72 Asset Management L.P., California State Teachers Retirement System, New York State Common Retirement Fund, Moore Capital Management LP, The Manufacturers Life Insurance Company , Schonfeld Strategic Advisors LLC, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Cogent Biosciences or view top insider-selling stocks.

Which institutional investors are buying Cogent Biosciences stock?

COGT stock was purchased by a variety of institutional investors in the last quarter, including Commodore Capital LP, Polar Capital Holdings Plc, Platinum Investment Management Ltd., Goldman Sachs Group Inc., Janus Henderson Group PLC, BlackRock Inc., Franklin Resources Inc., and AXA S.A..
View insider buying and selling activity for Cogent Biosciences or or view top insider-buying stocks.

How do I buy shares of Cogent Biosciences?

Shares of COGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cogent Biosciences' stock price today?

One share of COGT stock can currently be purchased for approximately $7.74.

How much money does Cogent Biosciences make?

Cogent Biosciences has a market capitalization of $308.45 million and generates $7.87 million in revenue each year. The technology company earns $-74.81 million in net income (profit) each year or ($7.31) on an earnings per share basis.

How many employees does Cogent Biosciences have?

Cogent Biosciences employs 15 workers across the globe.

What is Cogent Biosciences' official website?

The official website for Cogent Biosciences is www.cogint.com.

Where are Cogent Biosciences' headquarters?

Cogent Biosciences is headquartered at 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431.

How can I contact Cogent Biosciences?

Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company can be reached via phone at (617) 945-5576 or via email at [email protected].